Richardson P J, Kase H, Jenner P G
Pharmaceutical Development Centre, Kyowa Hakko Kogyo, Tokyo, Japan.
Trends Pharmacol Sci. 1997 Sep;18(9):338-44. doi: 10.1016/s0165-6147(97)01096-1.
There is now good reason to believe that blockade of the adenosine A2A receptor could be of value in the treatment of Parkinson's disease. Peter J. Richardson, Hiroshi Kase and Peter G. Jenner review the actions of this receptor in the striatum, emphasizing its ability to modulate the neuronal activity of striatal GABA-releasing output neurones, and showing that recently developed A2A receptor antagonists are capable of reducing the disabling effects of nigral cell degeneration in primates. They conclude that such antagonists may be useful as novel therapeutic agents for the treatment of Parkinson's disease.
现在有充分的理由相信，腺苷A2A受体的阻断在帕金森病的治疗中可能具有重要价值。彼得·J·理查森、 Hiroshi Kase和彼得·G·詹纳回顾了该受体在纹状体中的作用，强调其调节纹状体释放GABA的输出神经元的神经元活动的能力，并表明最近开发的A2A受体拮抗剂能够减轻灵长类动物黑质细胞变性的致残效应。他们得出结论，这种拮抗剂可能作为治疗帕金森病的新型治疗药物有用。
